{"Clinical Trial ID": "NCT00444587", "Intervention": ["INTERVENTION 1:", "Trastuzumab + 2nd line chemotherapy", "Eligible participants received trastuzumab 6 mg/kg body weight (except in Israel, where the dose was 2 mg/kg body weight), IV infusion every three weeks until disease progression, unacceptable toxicity or withdrawal from the study in combination with second-line chemotherapy."], "Eligibility": ["Incorporation criteria:", "* Female patients >= 18 years of age;", "Metastatic breast cancer;", "- HER2 overexpression (IHC 3+ and/or FISH positive);", "\u2022 Progression of the disease during or after the previous first line of chemotherapy + Herceptin;", "It is planned to receive second-line chemotherapy.", "- Exclusion criteria:", "Immunotherapy or simultaneous hormonal therapy;", "Anthracyclines as a result of prior chemotherapy of the 1st line or planned chemotherapy of the 2nd line;", "- Cardiac toxicity during chemotherapy previous 1st line + Herceptin;", "History of other malignities over the past 5 years."], "Results": ["Performance measures:", "Median time of disease progression", "The time required for the progression of the disease (TTP) in days was defined as the time elapsed between registration and objective progression of the disease (all categories other than objective progression of the disease were to be censored, including death before progression). The progression is defined using the criteria for assessing response in solid tumour criteria (RECIST v1.0), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the appearance of new lesions.", "Time limit: up to 5 years", "Results 1:", "Title of the arm/group: Trastuzumab + 2nd line of chemotherapy", "Description of the arm/group: Eligible participants received trastuzumab 6 mg/kg body weight (except in Israel, where the dose was 2 mg/kg body weight), IV infusion every three weeks until disease progression, unacceptable toxicity or withdrawal from the study in combination with second-line chemotherapy.", "Total number of participants analysed: 73", "Median (95% confidence interval)", "Unit of measurement: Computer days (n = 65): 171 (136 to 322)", "By researcher (n = 73): 171 (136 to 265)"], "Adverse Events": ["Undesirable Events 1:", "Total: 20/93 (21.51 per cent)", "Granulocytosis 1/93 (1.08%)", "Leucopenia 2/93 (2.15 per cent)", "Angine pectoris 0/93 (0.00 %)", "Atrial fibrillation 1/93 (1.08%)", "Cardiopulmonary failure 2/93 (2.15 per cent)", "Retinal Detachment 1/93 (1.08 per cent)", "Diarrhoea 3/93 (3.23%)", "Nausea 1/93 (1.08%)", "- Vomiting 1/93 (1.08 %)", "Chest pain 1/93 (1.08%)", "Deaths 0.13 (0.00 %)", "Pyrexia 1/93 (1.08%)"]}